Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 158 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations
Interventions
Social media recruitment, Self-Assessment, Follow-up
Behavioral
Lead sponsor
ZS Associates
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Evanston, Illinois
Conditions
Myasthenia Gravis, Generalized
Interventions
Claseprubart, Placebo
Drug
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • Irvine, California • Stamford, Connecticut + 16 more
Conditions
Myasthenia Gravis
Interventions
Placebo, 250 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Fresno, California • Orange, California • San Francisco, California + 12 more
Conditions
Myasthenia Gravis
Interventions
Exercise
Other
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Active, not recruiting Not applicable Interventional Results available

SP Thoracic IDE Study

NCT05150210
Conditions
Primary Lung Cancer, Benign Lung Disease, Thymoma, Myasthenia Gravis
Interventions
Robotic-Assisted Surgery
Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more
Conditions
Myasthenia Gravis
Interventions
Wearable sensor
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis
Interventions
Efgartigimod
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Lambert Eaton Myasthenic Syndrome (LEMS)
Interventions
3,4-diaminopyridine
Drug
Lead sponsor
Louis H. Weimer, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Conditions
Myasthenia Gravis
Interventions
Nipocalimab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
Conditions
Myasthenia Gravis, Myasthenia Gravis, Generalized
Interventions
Not listed
Lead sponsor
BioSensics
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Myasthenia Gravis
Interventions
ME&MGopen smartphone application
Device
Lead sponsor
Ad scientiam
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Generalized Myasthenia Gravis (gMG)
Interventions
Zilucoplan®
Drug
Lead sponsor
Miriam Freimer
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Tampa, Florida • Kansas City, Kansas • Columbus, Ohio
No Longer Available No phase listed Expanded access

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

NCT00704925
Conditions
Lambert Eaton Myasthenic Syndrome
Interventions
3, 4 DAP
Drug
Lead sponsor
David P. Richman, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Sacramento, California
Conditions
Generalized Myasthenia Gravis (gMG)
Interventions
CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Orange, California • Sacramento, California • San Francisco, California + 12 more
Completed No phase listed Observational Accepts healthy volunteers

Tissue Repository for Studies of Myasthenia Gravis

NCT02902536
Conditions
Myasthenia Gravis
Interventions
No interventions
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Myasthenia Gravis
Interventions
Telehealth
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 2 more
Conditions
Generalized Myasthenia Gravis, Myasthenia Gravis
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 130 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 14 more
Conditions
Generalized Myasthenia Gravis
Interventions
Telitacicept, Placebo
Biological · Drug
Lead sponsor
Vor Biopharma
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 22 more
Enrolling by invitation No phase listed Observational

Serum Auto-Antibodies in Neurological Diseases

NCT00704626
Conditions
Multiple Sclerosis, Myasthenia Gravis, Transverse Myelitis
Interventions
Blood Draw, Cheek swab
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2031
U.S. locations
1
States / cities
Sacramento, California
Conditions
Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke, Traumatic Brain Injury, Chronic Progressive External Ophthalmoplegia
Interventions
Magnetic Levator Prosthesis (MLP), Kinesiotape Frontalis Sling (KTFS)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
5 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Myasthenia Gravis
Interventions
IM-101 Part A, Placebo Part A, IM-101 Part B, Placebo Part B
Drug
Lead sponsor
ImmunAbs Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Altamonte Springs, Florida • Boca Raton, Florida • Naples, Florida + 4 more
Conditions
Refractory Generalized Myasthenia Gravis
Interventions
Eculizumab, Placebo
Biological · Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 22 more
Conditions
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 71 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Seattle, Washington
Conditions
Generalized Myasthenia Gravis
Interventions
M281
Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 20 more